
CITI TRAINING PRACTICE EXAM (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://cititraining.examzify.com

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright 1

Table of Contents 2

Introduction 3

How to Use This Guide 4

Questions 5

Answers 8

Explanations 10

Next Steps 15

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

SAMPLE

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

SAMPLE

Questions

SAMPLE

1. What does the ICH E6 guideline for good clinical practice provide?

A. A unified standard for archival of clinical trial documents

B. A unified standard for clinical trial design, conduct, recording, and reporting

C. Guidelines for pharmaceutical marketing

D. Guidelines for patient recruitment in clinical trials

2. What standards will the FDA apply?

A. The ICH E6 GCP standards

B. The Code of Federal Regulations

C. Local IRB requirements

D. State law where the sponsor's headquarters are located

3. When is it necessary for an investigator to complete and sign a new 1572?

A. Annually

B. At the end of the study

C. When participating in a new protocol added to the IND

D. When the study concludes

4. During the clinical development phase of the IND process, what must sponsors do?

A. Submit an NDA

B. Provide FDA with safety updates, copies of new protocols, FDA 1572, and Annual Progress reports

C. File a preclinical trial

D. Start the marketing phase

5. What is considered a "vulnerable population" in research?

A. Individuals with advanced degrees

B. Groups at risk of coercion or undue influence

C. Participants living in urban areas

D. Individuals over the age of 65 only

SAMPLE

6. What regulation must a principal investigator comply with to use an electronic data capture system for a clinical trial?

A. HIPAA

B. 21 CFR Part 11

C. FDA Guidelines

D. ICH GCP

7. What does "validation" refer to in research methodology?

A. The process of gathering data

B. Ensuring research instruments measure intended variables

C. The ability to replicate research findings

D. Reviewing literature before conducting research

8. How many seats does each of the 6 working groups of the ICH have on the Committee?

A. 2

B. 4

C. 6

D. 8

9. What is defined as 'Assent' in clinical trials?

A. The agreement from the trial sponsor.

B. Legal consent from a guardian.

C. The agreement of someone who cannot legally consent for themselves.

D. The refusal of a participant to continue in the trial.

10. What action did the FDA take in 2003 concerning Part 11 regulations?

A. Issued new guidelines for food safety

B. Implemented stricter controls on drug labeling

C. Withdrew guidance documents related to Part 11 for re-examination

D. Launched a campaign to improve clinical trial reporting

SAMPLE

Answers

SAMPLE

1. B
2. B
3. C
4. B
5. B
6. B
7. B
8. A
9. C
10. C

SAMPLE

Explanations

SAMPLE

1. What does the ICH E6 guideline for good clinical practice provide?

A. A unified standard for archival of clinical trial documents

B. A unified standard for clinical trial design, conduct, recording, and reporting

C. Guidelines for pharmaceutical marketing

D. Guidelines for patient recruitment in clinical trials

The ICH E6 guideline for good clinical practice provides a unified standard for clinical trial design, conduct, recording, and reporting. This includes guidelines for study design, data collection and management, as well as the ethical considerations and principles to be followed throughout the entire clinical trial process. Option A is incorrect because the guideline covers much more than just archival of documents. Option C is incorrect because the ICH E6 guideline is focused on the conduct of clinical trials, not pharmaceutical marketing. Option D is incorrect because while the guideline does address patient recruitment, it covers a much broader scope of topics related to clinical trials.

2. What standards will the FDA apply?

A. The ICH E6 GCP standards

B. The Code of Federal Regulations

C. Local IRB requirements

D. State law where the sponsor's headquarters are located

The FDA will apply the Code of Federal Regulations (CFR) standards in regulating drug development and clinical trials in the United States. The ICH E6 GCP standards (A) are guidelines developed by the International Council for Harmonisation and are not directly enforced by the FDA. While local IRB requirements (C) may also apply to clinical trials, they are not the primary standards used by the FDA in regulating drug development. State law (D) may also have an impact on clinical trials, but it is not the main set of standards used by the FDA. Therefore, the correct answer is B the Code of Federal Regulations.

3. When is it necessary for an investigator to complete and sign a new 1572?

A. Annually

B. At the end of the study

C. When participating in a new protocol added to the IND

D. When the study concludes

The 1572 is a form used by clinical investigators to indicate their agreement to follow certain procedures and regulations while conducting a clinical study. It is necessary for an investigator to complete and sign a new 1572 when participating in a new protocol added to the investigational new drug (IND) application. This is because the new protocol may have different procedures and regulations that the investigator needs to agree to. The other options, such as annually, at the end of the study, or when the study concludes, would not be accurate as they do not specifically address when a new protocol is added to the study. It is important for the investigator to review and sign a new 1572 in order to ensure that they are aware of and complying with all necessary procedures and regulations for the new protocol.

SAMPLE

4. During the clinical development phase of the IND process, what must sponsors do?

A. Submit an NDA

B. Provide FDA with safety updates, copies of new protocols, FDA 1572, and Annual Progress reports

C. File a preclinical trial

D. Start the marketing phase

During the clinical development phase of the IND process, sponsors are responsible for providing the FDA with safety updates, copies of new protocols, the FDA 1572 form, and Annual Progress reports. Option A is incorrect because an NDA (New Drug Application) is submitted during the marketing phase. Option C is incorrect because the preclinical trial is completed before the IND process begins. Option D is incorrect because the marketing phase starts after the IND process is completed and the drug is approved by the FDA. Therefore, the correct answer is B.

5. What is considered a "vulnerable population" in research?

A. Individuals with advanced degrees

B. Groups at risk of coercion or undue influence

C. Participants living in urban areas

D. Individuals over the age of 65 only

A "vulnerable population" in research refers to groups that are more likely to experience coercion or undue influence, making them susceptible to exploitation in the research context. This can include individuals with cognitive impairments, those living in poverty, ethnic minorities, children, and the elderly, among others. These populations may lack the capacity to provide informed consent or may be in a position where their ability to refuse participation may be compromised due to factors such as economic or social pressures. The term emphasizes the importance of ethical considerations ensuring that these individuals are protected from harm and that their participation is genuinely voluntary. Researchers must take extra steps to ensure that informed consent is obtained in an ethical manner, safeguarding participants' rights and well-being. In contrast, other groups mentioned, such as individuals with advanced degrees or those living in urban areas, are generally considered to be more empowered or have better access to resources, which decreases their vulnerability in the context of research. Individuals over the age of 65 do include vulnerable members, but not exclusively since not all older adults face the same level of risk or coercion, making the broader definition of groups at risk more encompassing and accurate.

SAMPLE

6. What regulation must a principal investigator comply with to use an electronic data capture system for a clinical trial?

A. HIPAA

B. 21 CFR Part 11

C. FDA Guidelines

D. ICH GCP

A HIPAA is the Health Insurance Portability and Accountability Act, which ensures the privacy and security of patient health information. While it is important for a principal investigator to comply with HIPAA in any clinical trial, it does not specifically address the use of electronic data capture systems. C: FDA Guidelines cover various aspects of clinical trials, including proper conduct, documentation, and approval processes, but they do not specifically address the use of electronic data capture systems. D: ICH GCP (International Council for Harmonisation Good Clinical Practice) is a set of ethical and scientific quality standards for designing, conducting, and reporting clinical trials. While it is important for a principal investigator to comply with ICH GCP in any clinical trial, it does not specifically address the use of electronic data capture systems. Therefore, the correct answer is B: 21 CFR Part 11, which specifically

7. What does "validation" refer to in research methodology?

A. The process of gathering data

B. Ensuring research instruments measure intended variables

C. The ability to replicate research findings

D. Reviewing literature before conducting research

Validation in research methodology refers to the process of ensuring that research instruments—such as surveys, tests, or measurement tools—accurately measure the intended variables they are designed to assess. It involves various techniques and assessments to confirm that the instruments are both reliable and valid, meaning they consistently produce accurate and meaningful results. This focus on measurement is crucial because if the instruments do not measure what they are supposed to, the data collected and the conclusions drawn from it may be flawed or misleading. Validation ensures that the findings of the research can be trusted and can contribute meaningful insights to the field of study. Gathering data, replicating research findings, and reviewing literature are important aspects of the research process, but they pertain to different phases or elements of research. Validation is specifically concerned with the integrity and appropriateness of the tools used for measurement within the research study.

8. How many seats does each of the 6 working groups of the ICH have on the Committee?

A. 2

B. 4

C. 6

D. 8

Each of the 6 working groups of the ICH have 2 seats on the Committee. This means that there are a total of 12 seats for the working groups on the Committee. It is important to note that the options of 4, 6, and 8 do not accurately reflect the total number of seats for working groups. Option B and D are not factors of 12, and option B is not a multiple of 2. Option C is also incorrect because it would result in a different number of seats for each working group. Therefore, option A is the correct answer as it accurately reflects the number of seats for each working group on the Committee.

SAMPLE

9. What is defined as 'Assent' in clinical trials?

A. The agreement from the trial sponsor.

B. Legal consent from a guardian.

C. The agreement of someone who cannot legally consent for themselves.

D. The refusal of a participant to continue in the trial.

Assent is defined as the agreement of someone who cannot legally consent for themselves, such as a minor or person with a cognitive impairment. This is different from legal consent, which is obtained from a guardian or sponsor. Option A is incorrect because the trial sponsor is responsible for organizing and funding the trial, not for providing assent. Option B is incorrect because it implies that legal consent and assent are interchangeable terms, when in fact they are distinct concepts. Option D is incorrect because it refers to refusal, which is the opposite of assent. Therefore, only option C correctly defines assent in clinical trials.

10. What action did the FDA take in 2003 concerning Part 11 regulations?

A. Issued new guidelines for food safety

B. Implemented stricter controls on drug labeling

C. Withdrew guidance documents related to Part 11 for re-examination

D. Launched a campaign to improve clinical trial reporting

In 2003, the FDA took action to withdraw guidance documents related to Part 11 regulations for re-examination. This means that they temporarily suspended the use of previous guidelines in order to review and revise them for better effectiveness and accuracy. This does not mean that the FDA completely abandoned their regulation of this area, but rather sought to improve and update it. Options A, B, and D are all incorrect because they do not reflect the specific action that the FDA took in regards to Part 11 regulations. In addition, they are also unrelated to the FDA's regulatory responsibilities, as food safety, drug labeling, and clinical trial reporting fall under different areas of their authority. Therefore, option C is the most appropriate and specific answer.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://cititraining.examzify.com

We wish you the very best on your exam journey. You've got this!

SAMPLE